MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-10-2026
Sonoma Pharmaceuticals Net Debt 2011-2026 | SNOA
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Sonoma Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.29 M | -2.84 M | -3.4 M | -6.84 M | -2.67 M | -2.21 M | -3.36 M | -9.8 M | -17.3 M | -7.36 M | -6.05 M | -5.33 M | -5.96 M | -112 K | -1.83 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -112 K | -17.3 M | -5.36 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Drug manufacturers industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-6.59 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Agile Therapeutics
AGRX
|
-676 K | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
-11.2 M | - | - | $ 142 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-22.5 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-11.1 M | - | - | $ 754 M | USA |
 |
Cronos Group
CRON
|
-1.07 B | $ 2.64 | -1.12 % | $ 1.36 B |  Canada |
 |
DURECT Corporation
DRRX
|
-10.4 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
2.43 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
7.37 B | - | - | $ 28.9 M |  Irlanda |
 |
Harrow Health
HROW
|
178 M | $ 40.9 | 0.91 % | $ 1.5 B | USA |
 |
Catalent
CTLT
|
4.58 B | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
-28.3 M | - | -23.39 % | $ 1.76 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-12.7 M | $ 4.36 | 4.06 % | $ 61.3 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-49.7 M | - | - | $ 2.06 B |  France |
 |
Jupiter Wellness
JUPW
|
-21.7 K | - | - | $ 33.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-931 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-150 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Pacira BioSciences
PCRX
|
317 M | $ 24.44 | -4.12 % | $ 1.13 B | USA |
 |
Solid Biosciences
SLDB
|
-38.7 M | $ 7.13 | -1.79 % | $ 624 M | USA |
 |
Evoke Pharma
EVOK
|
-2.96 M | - | - | $ 36.6 M | USA |
 |
Bausch Health Companies
BHC
|
21.1 B | $ 5.65 | -1.22 % | $ 2.06 B | Canada |
 |
Canopy Growth Corporation
CGC
|
193 M | $ 1.13 | 1.8 % | $ 122 M | Canada |
 |
Aurora Cannabis
ACB
|
285 M | $ 3.48 | 1.16 % | $ 86.3 M | Canada |
 |
Tilray
TLRY
|
14.4 M | $ 6.16 | -1.28 % | $ 3.81 B | Canada |
 |
Lannett Company
LCI
|
529 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
90.7 M | $ 1.42 | 0.71 % | $ 402 M | Canada |
 |
Veru
VERU
|
-20.9 M | $ 2.26 | 0.44 % | $ 305 M | USA |
 |
Evolus
EOLS
|
94.8 M | $ 5.33 | -1.11 % | $ 344 M | USA |
 |
Sundial Growers
SNDL
|
-28.4 M | $ 1.41 | 3.68 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
338 M | $ 8.47 | 2.67 % | $ 434 M | USA |
 |
Organogenesis Holdings
ORGO
|
-131 M | $ 2.57 | 9.36 % | $ 338 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-101 M | - | - | $ 193 M | Canada |
 |
cbdMD
YCBD
|
-521 K | $ 0.87 | 0.14 % | $ 3.75 M | USA |
 |
ProPhase Labs
PRPH
|
-6.41 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-111 M | - | - | $ 1.42 B | USA |
 |
Assertio Holdings
ASRT
|
29.1 M | $ 18.47 | 0.22 % | $ 118 M | USA |
 |
PetIQ
PETQ
|
329 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
-2.5 M | $ 7.64 | 1.6 % | $ 302 M | USA |
 |
Recro Pharma
REPH
|
-6.65 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-72.2 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-19.1 M | $ 0.99 | 6.48 % | $ 49.4 M | USA |
 |
PLx Pharma
PLXP
|
-21.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
16.8 B | $ 15.04 | 0.67 % | $ 18.1 B | USA |
 |
Zomedica Corp.
ZOM
|
-6.83 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-50.3 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-730 K | $ 0.89 | 1.29 % | $ 32 M | USA |
 |
Tricida
TCDA
|
-7.08 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-4.73 M | $ 0.53 | -2.39 % | $ 2.27 M |  China |
 |
TherapeuticsMD
TXMD
|
-1.39 M | $ 2.07 | 1.47 % | $ 23.9 M | USA |